Dexcom G6 is the first Continuous Glucose Monitoring (CGM) System to be listed by the NIHB Drug Benefit program. BURNABY, British Columbia--(BUSINESS WIRE)-- Dexcom, Inc. (NASDAQ: DXCM), a leader in ...
(COLORADO SPRINGS) — A medical device for diabetes called the Dexcom is facing a national shortage that’s now leaving diabetics in Southern Colorado frustrated. A Dexcom is responsible for monitoring ...
BURNABY, British Columbia--(BUSINESS WIRE)-- Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (CGM), is happy to share that people with type 1 diabetes who are ...
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--UpScriptHealth, the leading direct-to-patient telehealth company providing new distribution channels for pharmaceutical and medical device brands, announced today ...
San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing just under ...
BURNABY, British Columbia--(BUSINESS WIRE)--As of today, the Government of Saskatchewan’s expanded public coverage for continuous glucose monitoring (CGM) systems comes into effect. Dexcom, Inc.
Tuesday, the FDA approved DexCom Inc’s (NASDAQ:DXCM) Stelo Glucose Biosensor System as the first over-the-counter (OTC) continuous glucose monitor (CGM). The Dexcom Stelo Glucose Biosensor System is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback